Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

LukasWo Feb. 3 at 9:35 PM

$PSNL we are holding pretty strong today with everything going into panic mode. Here is a song dedicated to both the stock and our frustrated friends here - https://www.youtube.com/watch?v=wyzBOH24oZA

0 · Reply

degeneratetrader23 Feb. 3 at 8:08 PM

$PSNL i don't know why some here complain. Open up a 1 yr chart and you'll see it went from bottom left to top right.

1 · Reply

LucienW Feb. 3 at 7:37 PM

$PSNL here we are. There is probably more room to fall. But for anyone new here, I’m gonna repeat what I said last year when we were around $5 - this is probably where you wanna start your position, sure we are up almost 10x since the 2023 low but lots of things have changed with the company since then. Single digit won’t last forever

0 · Reply

LukasWo Feb. 3 at 5:51 PM

$PSNL and just added. screw you Goldman

0 · Reply

arribaStocktrading Feb. 3 at 5:39 PM

$PSNL What the market is saying today: You don't need Personalis. You don't need anything. All stocks are basically worthless. You just need AI. The doctor will be saying: "Take 2 A.I.'s and call me in the morning." No doubt to say you are cured. When the market behaves this stupidly, it can only mean one thing: Goldman Sachs is pulling the strings.

2 · Reply

Penki1985 Feb. 3 at 3:11 PM

$PSNL XBI breaking out of a bull flag so biotech sector clearly having some tailwinds in this skittish market

0 · Reply

LucienW Feb. 2 at 8:07 PM

$PSNL only ~3 weeks till the next conference call. Things don’t look so good right now unless there is another approval by then. Damn this wait has been such a torture. Ranting over

1 · Reply

NinjaXLightning Feb. 2 at 5:54 PM

$SGMO You only post about $PSNL, I doubt you ever even held SGMO…

2 · Reply

LukasWo Feb. 2 at 5:48 PM

$PSNL added a bit more

0 · Reply

ScarlettSignals1 Feb. 2 at 3:53 PM

$PSNL beaten biotech needs real accumulation signal before trusting upside

0 · Reply

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Jan 28, 2026, 4:01 PM EST - 6 days ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 12, 2026, 4:00 PM EST - 22 days ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Jan 8, 2026, 8:00 AM EST - 26 days ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dec 17, 2025, 6:00 AM EST - 6 weeks ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 11, 2025, 9:00 AM EST - 7 weeks ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Nov 18, 2025, 4:01 PM EST - 2 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 3 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 4, 2025, 9:46 PM EST - 3 months ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 3 months ago

Personalis Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 3 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Oct 16, 2025, 9:00 AM EDT - 3 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Sep 15, 2025, 5:35 PM EDT - 5 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:05 PM EDT - 5 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 5 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 5 months ago

Personalis to Participate in Upcoming Investor Conferences

Aug 6, 2025, 8:11 AM EDT - 6 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Aug 5, 2025, 10:49 PM EDT - 6 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 6 months ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 7 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 4:00 PM EDT - 7 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 8 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 8 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 9 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 9 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 8:41 PM EDT - 9 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 9 months ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 10 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 10 months ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 10 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 11 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 1 year ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 7:40 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 4:21 PM EST - 1 year ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Feb 18, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 14, 2025, 10:50 AM EST - 1 year ago

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 13, 2025, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 1 year ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

LukasWo Feb. 3 at 9:35 PM

0 · Reply

degeneratetrader23 Feb. 3 at 8:08 PM

$PSNL i don't know why some here complain. Open up a 1 yr chart and you'll see it went from bottom left to top right.

1 · Reply

LucienW Feb. 3 at 7:37 PM

0 · Reply

LukasWo Feb. 3 at 5:51 PM

$PSNL and just added. screw you Goldman

0 · Reply

arribaStocktrading Feb. 3 at 5:39 PM

2 · Reply

Penki1985 Feb. 3 at 3:11 PM

$PSNL XBI breaking out of a bull flag so biotech sector clearly having some tailwinds in this skittish market

0 · Reply

LucienW Feb. 2 at 8:07 PM

$PSNL only ~3 weeks till the next conference call. Things don’t look so good right now unless there is another approval by then. Damn this wait has been such a torture. Ranting over

1 · Reply

NinjaXLightning Feb. 2 at 5:54 PM

$SGMO You only post about $PSNL, I doubt you ever even held SGMO…

2 · Reply

LukasWo Feb. 2 at 5:48 PM

$PSNL added a bit more

0 · Reply

ScarlettSignals1 Feb. 2 at 3:53 PM

$PSNL beaten biotech needs real accumulation signal before trusting upside

0 · Reply

JFDI Feb. 2 at 3:41 PM

$PSNL higher low? lmao...

1 · Reply

Londonlight Feb. 2 at 11:50 AM

$PSNL i feel sick

1 · Reply

Wax_Bean_futures Feb. 2 at 11:28 AM

$PSNL https://www.businesswire.com/news/home/20260202837412/en/Personalis-Announces-New-Publication-Expanding-Evidence-for-Ultrasensitive-ctDNA-Monitoring-of-Cancer-Immunotherapy-Response-Across-Solid-Tumors

0 · Reply

RockyMontana Feb. 2 at 7:30 AM

$PSNL okay maybe we'll just be fine.

0 · Reply

RockyMontana Feb. 2 at 6:06 AM

$PSNL are we screwed with gold, silver, btc on a falling knife?

2 · Reply

magnitudeFC Jan. 30 at 6:47 PM

$PSNL lmao who jinxed it calling out double digits? 😂

0 · Reply

lucianw Jan. 30 at 3:31 PM

$PSNL added

1 · Reply

LukasWo Jan. 30 at 3:24 PM

$PSNL added 1k shares at 9.4

1 · Reply

Wax_Bean_futures Jan. 30 at 3:20 PM

$PSNL Is the market gonna make me add more?

2 · Reply

OfficialStocktwitsUser Jan. 30 at 12:33 PM

$PSNL RSI: 63.11, MACD: 0.4201 Vol: 0.94, MA20: 9.30, MA50: 9.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechNoir Jan. 30 at 1:57 AM

$PSNL holding for $48 to match my age 🤠🤣

1 · Reply

Wax_Bean_futures Jan. 29 at 4:40 PM

$PSNL This and PRME are my only green holdings today. I'll take it

1 · Reply

Market Cap	832.09M
Revenue (ttm)	84.61M
Net Income (ttm)	-81.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.06%
Debt to Equity Ratio	0.00

Volume	811,000
Avg Vol	1,407,804
Day's Range	N/A - N/A
Shares Out	88.80M
Stochastic %K	12%
Beta	1.96
Analysts	Strong Sell
Price Target	$11.14